Belluscura (BELL)

Sector:

Health Care

Index:

FTSE AIM All-Share

7.17p
   
  • Change Today:
    -0.083p
  • 52 Week High: 50.00
  • 52 Week Low: 7.11
  • Currency: UK Pounds
  • Shares Issued: 165.03m
  • Volume: 153,788
  • Market Cap: £11.83m

Belluscura oxygen concentrator approved in Singapore

By Josh White

Date: Tuesday 12 Dec 2023

LONDON (ShareCast) - (Sharecast News) - Belluscura, a medical device developer specialising in portable oxygen enrichment technology, announced approval from the Singapore Health Sciences Authority to distribute its 'X-PLOR' portable oxygen concentrator (POC) in Singapore.
The AIM-traded firm said the milestone followed the signing of an exclusive licence agreement with InnoMax Medical Device Technologies in August, encompassing Singapore as one of the territories.

Under the agreement, InnoMax would pay minimum royalties and a share of profits for the X-PLOR device and associated accessories.

Chronic obstructive pulmonary disease (COPD) affects about 5.9% of adults over 40 years old in Singapore, though Belluscura said the figure was believed to be an underestimate due to undiagnosed cases.

It added that Singapore's location would provide a gateway to other ASEAN countries granting expedited review to medical devices approved in Singapore, such as Thailand and the Philippines.

Looking at the broader region, Thailand has more than one million COPD sufferers, while the medical oxygen systems market in the Philippines was projected to experience a compound annual growth rate of 7.1%, reaching $86m.

That growth was attributed to the rising prevalence of respiratory diseases stemming from air pollution and smoking, resulting in increased demand for oxygen therapy systems among COPD patients.

Belluscura said it was committed to expanding its regional presence and marketing its POCs, including the DISCOV-R.

"We are very excited to receive this approval, enabling us to launch sales in Singapore, as a first market in the ASEAN region," said chief executive officer Bob Rauker.

"With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing region."

At 1521 GMT, shares in Belluscura were up 13.9% at 23.35p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Belluscura Market Data

Currency UK Pounds
Share Price 7.17p
Change Today -0.083p
% Change -1.15 %
52 Week High 50.00
52 Week Low 7.11
Volume 153,788
Shares Issued 165.03m
Market Cap £11.83m

Belluscura Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.88% above the market average48.88% above the market average48.88% above the market average48.88% above the market average48.88% above the market average
56.25% above the sector average56.25% above the sector average56.25% above the sector average56.25% above the sector average56.25% above the sector average
Price Trend
97.24% below the market average97.24% below the market average97.24% below the market average97.24% below the market average97.24% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Income Not Available
Growth
22.55% above the market average22.55% above the market average22.55% above the market average22.55% above the market average22.55% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

Belluscura Dividends

No dividends found

Trades for 01-May-2024

Time Volume / Share Price
10:21 43,329 @ 7.11p
10:05 82 @ 7.50p
09:10 13,610 @ 7.11p
08:46 15,000 @ 7.11p
08:02 81,767 @ 7.34p

Belluscura Key Personnel

CEO Robert “Bob” Rauker
CFO Simon Neicheril

Top of Page